Elsevier

Journal of Psychiatric Research

Volume 31, Issue 2, March–April 1997, Pages 233-256
Journal of Psychiatric Research

Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics

https://doi.org/10.1016/S0022-3956(96)00041-6Get rights and content

Abstract

Limbic cortical regions, including anterior cingulate cortex (ACC), prefrontal cortex (PFC) and entorhinal cortex (ERC), have been implicated in the neuropathology of schizophrenia. Glutamate projection neurons connect these limbic cortical regions to each other, as well as to the terminal fields of the striatal/accumbens dopamine neurons. Subsets of these glutamate projection neurons, and of the GABA interneurons in cortex, contain the neuropeptide cholecystokinin (CCK). In an effort to study the limbic cortical glutamate projection neurons and GABA interneurons in schizophrenia, we have measured CCK mRNA with in situ hybridization histochemistry in postmortem samples of dorsolateral (DL)PFC, ACC and ERC of seven schizophrenics, nine nonpsychotic suicides and seven normal controls. CCK mRNA is decreased in ERC (especially layers iii–vi) and subiculum in schizophrenics relative to controls. Cellular analysis indicates that there is a decrease in density of CCK mRNA in labelled neurons. In so far as ERC CCK mRNA is not reduced in rats treated chronically with haloperidol, this decrease in schizophrenics does not appear to be related to neuroleptic treatment. In contrast, in DLPFC, where schizophrenics do not differ from normals, the suicide victims have elevated CCK mRNA (especially in layers v and vi), and increased cellular density of CCK mRNA, relative to both normals and schizophrenics. These results lend further support for the involvement of ERC and hippocampus in schizophrenia, suggesting that neurons that utilize CCK may be particularly important. Similarly, an increase in CCK mRNA levels in the PFC of suicides adds to a growing body of evidence implicating this structure in this pathological state. In so far as CCK is co-localized with GABA or glutamate in cortical neurons, both of these neuronal populations need to be studied further in schizophrenia and suicide.

References (166)

  • P. Falkai et al.

    Limbic pathology in schizophrenia: the entorhinal region- a morphometric study

    Biol Psychiatry

    (1988)
  • S.M. Farmery et al.

    Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients

    Life Sci

    (1985)
  • K. Fredens et al.

    Localization of enkephalin and cholecystokinin immunoreactivities in the perforant path terminal fields of the rat hippocampal formation

    Brain Res

    (1984)
  • P. Frey

    Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment

    Eur J Pharmacol

    (1983)
  • P.S. Goldman-Rakic et al.

    Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey

    Neuroscience

    (1984)
  • K. Gysling et al.

    Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tubercle-nucleus accumbens area

    Neuropeptides

    (1984)
  • S. Hanada et al.

    [3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics

    Life Sci

    (1987)
  • P.J. Harrison et al.

    Decreased hippocampal expression of a glutamate receptor gene in schizophrenia

    Lancet

    (1991)
  • S.E. Hays et al.

    Localization of cholecystokinin receptors on neuronal elements in rat caudate nucleus

    Brain Res

    (1981)
  • T. Hökfelt et al.

    A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing

    Neuroscience

    (1980)
  • R.S.G. Jones

    Entorhinal-hippocampal connections: a speculative view of their function

    Trends Neurosci

    (1993)
  • E.G. Jones et al.

    Co-localization of GABA and neuropeptides in neocortical neurons

    Trends Neurosci

    (1986)
  • Y. Kawasaki et al.

    SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test

    Schizophr Res

    (1993)
  • R. Kerwin et al.

    Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem

    Neuroscience

    (1990)
  • N. Ladurelle et al.

    Different modifications of the dopamine metabolism in the core and shell parts of the nucleus accumbens following CCK-A receptor stimulation in the shell region

    Neurosci Lett

    (1994)
  • R.Z. Liang et al.

    Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin

    Brain Res

    (1991)
  • P.L. McGeer et al.

    A glutamatergic corticostriatal path?

    Brain Res

    (1977)
  • D.K. Meyer et al.

    Corpus callosum lesions increase cholecystokinin concentrations in cortical areas with homeotopic connections

    Brain Res

    (1982)
  • J.A. Miller

    The calibration of 35S or 32P with 14C-labeled brain paste or 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm

    Neurosci Lett

    (1991)
  • N.P.V. Nair et al.

    Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study

    Prog Neuropsychopharmacol Biol Psychiatry

    (1984)
  • C.E. Adams et al.

    Sources of neostriatal cholecystokinin in the cat

    J Comp Neurol

    (1990)
  • S. Akbarian et al.

    Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development

    Arch Gen Psychiatry

    (1993)
  • S. Akbarian et al.

    Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development

    Arch Gen Psychiatry

    (1993)
  • S. Akbarian et al.

    Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics

    Arch Gen Psychiatry

    (1995)
  • M. Albus et al.

    Ceruletide: a new drug for the treatment of schizophrenic patients?

    Arch Gen Psychiatry

    (1984)
  • L.L. Altshuler et al.

    The hippocampus and parahippocampus in schizophrenic, suicide, and control brains

    Arch Gen Psychiatry

    (1990)
  • S.E. Arnold et al.

    Abnormal expression of two microtubule-associated proteins (MAP-2 and MAP-5) in specific subfields of the hippocampal formation in schizophrenia

  • C. Baleydier et al.

    The duality of the cingulate gyrus in monkey: neuroanatomical study and functional hypothesis

    Brain

    (1980)
  • F.M. Benes et al.

    Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics

    Arch Gen Psychiatry

    (1986)
  • F.M. Benes et al.

    Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain

    Cereb Cortex

    (1992)
  • F.M. Benes et al.

    Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics

    J Neurosci

    (1992)
  • T.W. Blackstad

    Commissural connections of the hippocampal region in the rat, with special reference to their mode of termination

    J Comp Neurol

    (1956)
  • D.M. Bloom et al.

    CCK-8 in the treatment of chronic schizophrenia

    Psychopharmacol Bull

    (1983)
  • B. Bogerts

    Zur Neuropathologie der Schizophrenien

    Fortschr Neurol Psychiatr

    (1984)
  • B. Bogerts

    Limbic & paralimbic pathology in schizophrenia: interaction with age- and stress-related factors

  • B. Bogerts et al.

    Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage

    Arch Gen Psychiatry

    (1985)
  • R.A. Boza et al.

    Is cholecystokinin therapeutic in chronic schizophrenia?

    J Clin Psychiatry

    (1985)
  • R. Brown et al.

    Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder

    Arch Gen Psychiatry

    (1986)
  • J.-M. Burgunder et al.

    Cortical neurons expressing the cholecystokinin gene in the rat: distribution in the adult brain, ontogeny, and some of their projections

    J Comp Neurol

    (1990)
  • M.F. Casanova et al.

    Quantitative shape analysis of the temporal and prefrontal lobes of schizophrenic patients: a magnetic resonance image study

    J Neuropsychiatry Clin Neurosci

    (1990)
  • Cited by (68)

    • Regional differences in expression of β-tubulin isoforms in schizophrenia

      2012, Schizophrenia Research
      Citation Excerpt :

      Regionally divergent changes in gene expression are not without precedent. Several other studies have found an increase in various gene expression products in one area, and a decrease in another, suggesting that changes in the brain in schizophrenia are not global, but may be region specific (Bachus et al., 1997; Katsel et al., 2005a, 2005b; Kristiansen et al., 2006; Bauer et al., 2008; Oni-Orisan et al., 2008; Kristiansen et al., 2010). To explore the hypothesis that changes in βI-tubulin are regionally specific, we examined βI-tubulin protein expression in two other regions, the STG and HC.

    • Anxiogenic effect of CCK8s in the ventral hippocampus of rats: Possible involvement of GABA<inf>A</inf> receptors

      2012, Pharmacological Reports
      Citation Excerpt :

      CCK is involved in the regulation of various physiological and cognitive functions such as anxiety, learning and memory, thermoregulation, analgesia and satiety [2]. Cholecystokinin mRNA is decreased in the brain of schizophrenics [1] and its concentration in the brain change during Alzheimer’s disease [23] confirming the active role of CCK in the etiology of psychological disorders. This neuropeptide has an important role in the regulation of anxiety-related behavior [8, 37].

    • Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats

      2011, Behavioural Brain Research
      Citation Excerpt :

      An alternative explanation for increased plasma CCK levels may be related to the therapeutic mechanisms by which olanzapine can treat schizophrenia, as decreased CCK may play a role in the disease pathophysiology. For example, schizophrenia patients have low cerebrospinal fluid levels of CCK [83] and decreased CCK mRNA expression in the temporal, frontal and entorhinal cortices [84,85]. Olanzapine treatment had no effect on the level of circulating PYY(3–36), which coincides with findings in male patients [27].

    View all citing articles on Scopus
    View full text